山東新華製藥股份(00719.HK):鹽酸左沙丁胺醇霧化吸入溶液獲批
格隆匯1月20日丨山東新華製藥股份(00719.HK)發佈公吿,近日,新華製藥收到國家藥品監督管理局核准簽發的鹽酸左沙丁胺醇霧化吸入溶液《藥品補充申請批准通知書》,該產品上市許可持有人轉讓申請獲得批准。鹽酸左沙丁胺醇霧化吸入溶液於2025年1月通過國家藥品監督管理局審批,新華製藥成為本品的上市許可持有人。該產品的上市,有利於豐富公司呼吸系統藥物產品線,提升公司綜合競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.